ArticleProceedings of the National Academy of Sciences of the United States of America2005
Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders.Nature human behaviour · 2024Pooled it
- Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement.Pharmacogenomics · 2010Trial
- Molecular genetics of successful smoking cessation: convergent genome-wide association study results.Archives of general psychiatry · 2008Trial
- Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs.BMC genetics · 2007Trial
- Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes.Molecular medicine (Cambridge, Mass.)Trial
- Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.Molecular medicine (Cambridge, Mass.)Trial
- Identification of variants from gene expression data of opioid-addicted patients.Journal of applied genetics · 2026Article
- Pentilludin reduces rat amphetamine and remifentail self-administration with good pharmacologic and toxicologic profiles.bioRxiv : the preprint server for biology · 2025Article
- Structure, function, and pathology of Neurexin-3.Genes & diseases · 2023Review
- Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D.Frontiers in psychiatry · 2023Review
- Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.Biochemical pharmacology · 2022Article
- Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.Expert opinion on drug metabolism & toxicology · 2021Review
- PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.Annals of the New York Academy of Sciences · 2019Review
- Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- The Role of Cell Adhesion Molecule Genes Regulating Neuroplasticity in Addiction.Neural plasticity · 2018Review
- Neuroepigenetics and addiction.Handbook of clinical neurology · 2018Review
- Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions.Molecular psychiatry · 2016Review
- Implications of genome wide association studies for addiction: are our a priori assumptions all wrong?Pharmacology & therapeutics · 2013Review
- Comparison of genotyping using pooled DNA samples (allelotyping) and individual genotyping using the affymetrix genome-wide human SNP array 6.0.BMC genomics · 2013Article
- Examining the association of NRXN3 SNPs with borderline personality disorder phenotypes in heroin dependent cases and socio-economically disadvantaged controls.Drug and alcohol dependence · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Association genome scanning is of increasing interest for identifying the chromosomal regions that contain gene variants that contribute to vulnerability to complex disorders, including addictions. To improve the power and feasibility of this approach, we have validated "10k" microarray-based allelic frequency assessments in pooled DNA samples and have used this approach to seek allelic frequency differences between heavy poly-substance abusers and well characterized control individuals. Thirty-eight loci contain SNPs that display robust allele frequency differences between abusers and controls in both European- and African-American samples. These loci identify an alcohol/acetaldehyde dehydrogenase gene cluster and genes implicated in cellular signaling, gene regulation, development, "cell adhesion," and Mendelian disorders. The results converge with previous linkage and association results for addictions. Pooled association genome scanning provides a useful tool for elucidating molecular genetic underpinnings of complex disorders and identifies both previously understood and previously unanticipated mechanisms for addiction vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.